Oslo-CoMet: Oslo Randomized Laparoscopic Versus Open Liver Resection for Colorectal Metastases Study

Sponsor
Oslo University Hospital (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT01516710
Collaborator
Helse Sor-Ost (Other)
280
1
2
167
1.7

Study Details

Study Description

Brief Summary

The purpose of the study is to compare outcomes of laparoscopic versus open liver resection for colorectal metastases in a prospective and randomized study. The study will include all non-anatomic liver resections in our institution.

The primary end point is that the use of laparoscopic technique significantly can reduce the frequency of complications to liver resection. Secondary end points are 5-year survival, immediate surgical outcomes, quality of life and degree of impairment of the immune system.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Open liver resection
  • Procedure: Laparoscopic liver resection
N/A

Detailed Description

Full protocol is published open access in Trialsjournal:

http://www.trialsjournal.com/content/16/1/73

Study Design

Study Type:
Interventional
Actual Enrollment :
280 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Prospective Randomized Study of Laparoscopic Versus Open Liver Resection for Colorectal Metastases
Study Start Date :
Jan 1, 2012
Actual Primary Completion Date :
Apr 1, 2016
Anticipated Study Completion Date :
Dec 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Open liver resection

Patients will be operated with open liver resection

Procedure: Open liver resection
Patients will be operated with open liver resection for colorectal metastasis
Other Names:
  • Open liver resection using standard technique:
  • Ligasure
  • CUSA
  • Thunderbeat
  • Autosonix
  • SonoSurg
  • Ultrasound
  • Active Comparator: Laparoscopic liver resection

    Patients will be operated with laparoscopic liver resection

    Procedure: Laparoscopic liver resection
    Patients will be operated with laparoscopic liver resection
    Other Names:
  • Laparoscopic liver resection using standardized technique:
  • Ligasure
  • CUSA
  • Thunderbeat
  • Autosonix
  • SonoSurg
  • Laparoscopic ultrasound
  • Outcome Measures

    Primary Outcome Measures

    1. Perioperative morbidity [Within 30 days after surgery]

      This study aims to compare major intraoperative and postoperative parameters in patients randomized to either laparoscopic or open liver resection. Pre- and perioperative events relevant for surgical outcomes will be registered. The following intraoperative parameters will be compared: operative time, blood loss, blood transfusion, while intraoperative incidents will be classified according to the Satava classification. Morbidity within the first 30 days is the primary outcome (morbidity, yes/no), and will be classified and analysed according to the validated classification for postoperative morbidity as described by Dindo et al, by the Accordion system and by the Comprehensive Complication Index

    Secondary Outcome Measures

    1. 5 year survival [5 years after surgery]

      5 year survival overall disease free recurrence free

    2. Recurrence pattern [5 years]

      Pattern of recurrence in liver and extrahepatic. Studied by postoperative CT every 4 months for 2 years and every 6 months for the following 3 years. Local recurrence and new tumors will be recorded.

    3. Immediate oncologic outcome [2 months after surgery]

      Immediate oncologic outcome is the result of surgical specimen evaluation - evaluation of tumor resection margins.

    4. Postoperative quality of life [Up to 2 years]

      Evaluation of postoperative quality of life at baseline, 1 month, 4 months and 2 years using the SF-36 and the EORTC qlq-30 lmc-21 forms

    5. Surgical trauma and activation of the immune system [72 hours]

      Evaluation of surgical trauma caused by open and laparoscopic resection by means of analyzing complement and cytokine activation at set perioperative time points.

    6. Health economy [1 year]

      We intend to compare overall cost of treatment for the hospital and for the health care system

    7. Severity of postoperative pain [4 months]

      To compare pain the first 5 postoperative days, at 1 month and 4 months. Patients in the open group will be randomized to receiving either a patient controlled analgesic pump containing opioids, or a patient controlled epidural analgesic pump. In laparoscopic group all patients will receive a PCA.

    8. Molecular biology [20 years]

      The aim is to perform molecular characterization of biological samples harvested perioperatively and during follow-up, and to correlate results with clinical end points.

    9. Anti-tumor immunology [20 years]

      The aim is to evaluate immunological parameters related to anti-tumor immunity and inflammatory factors

    10. Imaging [5 years]

      The aim is to evaluate two new imaging methods, CT perfusion of liver and LIME-PET, in order to optimize the preoperative identification of colorectal liver metastases.

    11. Severity of morbidity [30 days]

      Severity of complications will be assessed by the Comprehensive Complication Index and the Accordion system

    12. Level of adhesions [2 years]

      Level of adhesions will be recorded during repeated liver resection in patients formerly randomized to open or laparoscopic liver resection. a modified version of the peritoneal adhesion index will be used for scoring.

    13. Number of patients that complete adjuvant oncologic treatment [1 year]

      Time from operation to initiation of oncologic treatment, and the total number of courses given will be recorded and compared between the groups.

    14. Readmissions [30 days]

      Readmissions within 30 days after surgery will be recorded, both admissions to Oslo University Hospital and to referring hospitals.

    15. Incidence of incisional hernia [1 year]

      CT scans will be performed to examine for incisional hernia 1 year after surgery

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients eligible for radical liver resection without formal liver resection or without assistance of radiofrequency ablation
    Exclusion Criteria:
    • Inability to give written informed concent

    • Patients with tumors that can't be resected without reconstruction of vessels or bile ducts

    • Patients with tumors that can't be resected without 1)formal liver resection 2)combination with radiofrequency ablation

    • Patients with extrahepatic metastasis except resectable metastasis in lungs and adrenals

    • Pre- and peroperative diagnosis of non radically treatable disease

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Oslo University Hospital, Department of Gastrointestinal surgery, The National Hospital Oslo Norway 0424

    Sponsors and Collaborators

    • Oslo University Hospital
    • Helse Sor-Ost

    Investigators

    • Study Chair: Bjørn Edwin, MD, PhD, Oslo University Hospital - The Interventional Centre
    • Principal Investigator: Bjorn Edwin, MD, PhD, Oslo University Hospital - The Interventional Centre

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Åsmund Avdem Fretland, MD, Oslo University Hospital
    ClinicalTrials.gov Identifier:
    NCT01516710
    Other Study ID Numbers:
    • 2011/1285/REK sør-øst B
    First Posted:
    Jan 25, 2012
    Last Update Posted:
    Jan 6, 2017
    Last Verified:
    Jan 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Keywords provided by Åsmund Avdem Fretland, MD, Oslo University Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 6, 2017